bluebird bio (BLUE) registered revenues of $18.6 million in the first quarter, up from $2.4 million recorded in the year-ago quarter and beating the Zacks Consensus Estimate of $18 million.The $16.2-million upside can be attributed to increased Zynteglo product revenues.The FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusion on Aug 17, 2022, and Skysona for treating early, active cerebral adrenoleukodystrophy (CALD) on Sept ...